International Stem Cell Corporation (ISCO.ob) is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first Parthenogenic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. - (Read more)

Athersys (Nasdaq: ATHX) is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support.   - (Read more)

Geron (Nasdaq: GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. - (Read more)

Osiris Therapeutics, Inc. (OSIR) is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas.  Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.
- (Read more)

StemCells, Inc. (Nasdaq: STEM) is focused on the discovery and development of stem cell therapeutics to treat damage to or degeneration of major organ systems such as the Central Nervous System, Liver and Pancreas. - (Read more)

Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside. - (Read more)

Neuralstem, Inc. (AMEX: CUR) is a publicly traded biotherapeutics company whose mission is to apply stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system including Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinson’s Disease. - (Read more)

Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions (BLFS) develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) media products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development. The Company’s proprietary HypoThermosol and CryoStor platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. US FDA Master Files are available for cross-reference. BioLife’s enabling technology provides research and clinical customers significantly extended storage stability and improved post-preservation viability and recovery of cells, tissues, and organs. For more information please visit www.biolifesolutions.com. - (Read more)

At ThermoGenesis (Nasdaq: KOOL), we know how valuable stem cells can be—and that there is only one chance to get it right. So for over 20 years, we’ve dedicated ourselves to providing clinicians, researchers, hospitals, and blood banks with systems designed to handle stem cells with the highest levels of precision, safety, and confidence.

From today’s cells to tomorrow’s solutions, count on our technologies to help you put a new world of innovative therapies into circulation. - (Read more)

BioTime, Inc. (NYSE AMEX: BTIM) is a biotechnology company engaged in two areas of biomedical research and product development:

- Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.

- Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us.
- (Read more)

BrainStorm (BCLI.PK) is an emerging company developing stem cell therapeutic products based on breakthrough technologies. BrainStorm's core technology, NurOwn™, was developed through a collaboration between prominent neurologist, Prof. Eldad Melamed, Head of Neurology of the Rabin Medical Center and member of the Scientific Committee of Michael J. Fox Foundation for Parkinson's Research and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University.

This scientific team is among the first to have successfully demonstrated the physiological release of dopamine from in vitro differentiated bone marrow cells. Moreover, in research conducted by this team, implantation of these cells into the brains of animal models that had been induced to Parkinsonian behavior markedly improved their symptoms. BrainStorm intends to apply the patent-pending technology to the development of innovative autologous cell therapeutic products, NurOwn™, for treatment of neurological diseases. - (Read more)

Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft® products are available in North America and Europe for fat grafting procedures.

Founded in 1989 with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options. - (Read more)

Pluristem Therapeutics Inc. (Nasdaq: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20-million patients of Peripheral Artery Disease (PAD) market.

The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.